Every notice published to our newspaper and news site also appears on funeral-notices.co.uk - the UK’s number one site for ...

As temperatures rose in more than a dozen Middle Eastern and North African countries over the past two decades, cancer mortality among women did too, according to a new study.

BOSTON - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company currently valued at $311 million, has announced promising preclinical results for its novel ...

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and ...

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compare ...

Additionally, Monte Rosa shared updates on its clinical programs, including promising early results from its MRT-2359 study in castration-resistant prostate cancer patients.

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR ...